Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
Status:
NOT_YET_RECRUITING
Trial end date:
2031-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals tumor cells to multiply. This helps stop the spread of tumor cells. This trial may help doctors determine the best dosing strategy for patients who have received dabrafenib and trametinib for 12-24 months: Either stopping dabrafenib and trametinib completely or slowly reducing the dose for an additional 6 months.
Phase:
PHASE2
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
Rising Tide Foundation
Treatments:
dabrafenib Magnetic Resonance Spectroscopy Specimen Handling trametinib